Elsy sells ZIOP 9.8: ZIOPHARM Oncology (NASDAQ:ZIOP) traded up 2.61% on Monday, hitting $8.66. The stock had a trading volume of 5,504,863 shares.

The shares were sold at an average price of $9.70, for a total value of $388,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other ZIOPHARM Oncology news, Director Murray Brennan sold 40,000 shares of the business's stock in a transaction dated Thursday, June 4th. Vetr's target price would suggest a potential upside of 61.66% from the stock's current price. The brokerage currently has a $14.00 price target on the biotechnology company's stock. Finally, Guggenheim started coverage on shares of ZIOPHARM Oncology in a research note on Wednesday, May 13th.


Jenna:
ZIOPHARM Oncology, Inc. is a biotechnology company employing gene expression and control technology to deliver DNA for the treatment of cancer.

Shelley:
The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.11. On average, analysts expect that ZIOPHARM Oncology will post ($0.51) EPS for the current year.

Sidney:
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, August 10th.

Karl:
Finally, Mizuho reissued a neutral rating and set a $10.00 target price (down from $14.00) on shares of ZIOPHARM Oncology in a research note on Wednesday, June 10th.

Miki:
BMO Capital Markets restated an outperform rating and issued a $15.00 price target on shares of ZIOPHARM Oncology in a research report on Sunday, May 10th.

Shanti:
Guggenheim began coverage on shares of ZIOPHARM Oncology in a research report on Wednesday, May 13th.

Bette:
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Monday, August 10th.

Hassie:
ZIOPHARM Oncology Inc. ( NASDAQ:ZIOP ) traded down 13.59% during mid-day trading on Tuesday, reaching $10.30. 4,724,898 shares of the company traded hands.

Roseanne:
They now have a $10.00 price target on the stock, down previously from $15.00. They noted that the move was a valuation call.

Viva:
In addition, on July 31, 2015, the Company received $57.5 million from Intrexon related to the Merck Serono agreement.

Ziopharm Oncology Inc (NASDAQ:ZIOP)
//stockhand.net/us/?q=nasdaq%3Aziop&id=296911